Antiretroviral therapy (ART) is a kind of treatment using anti-HIV drugs for people who infect with human immunodeficiency virus (HIV). Continuous improvements in ART have transformed HIV infection from a debilitating fatal disease into a chronic treatable disease[@b1][@b2]. In spite of the fact that majority of acquired immunodeficiency syndrome (AIDS) patients benefit from ART, in resource-limited countries, the proportion of patients who switch their ARTs from first-line to second-line when failing the first-line regimen is increasing. Earlier detection of treatment failure and switching to second-line protease-inhibitor (PI) -based ART probably reduces mortality[@b3][@b4][@b5][@b6]. LPV/r (a co-formulation of lopinavir and ritonavir) is the first ritonavir-boosted PI and is most widely used as a standard comparator for other boosted PI regimens. Several randomized controlled trials (RCTs) have described clinical outcomes of patients on first-line[@b7][@b8][@b9][@b10][@b11][@b12][@b13][@b14] and second-line therapy[@b15][@b16][@b17][@b18]. Hence, the primary purpose of the present meta-analysis is to evaluate the effectiveness of lopinavir/ritonavir (LPV/r)-based regimens for treatment-naïve HIV-1-infected patients or ART-experienced patient from reported RCTs. PI-based and nucleoside reverse transcriptase inhibitors (NRTI)-containing regimens have also been associated with metabolic perturbations, including hyperlipidemia, insulin resistance, and fat redistribution[@b7][@b8][@b12]. Considering these metabolic perturbations, another important objective of the study is to evaluate the toxicity related to LPV/r-based ART regimen, focusing on the lipid profile.

Further, it was noticed that there are no adequate studies related to HIV-infected pregnant women. Clinical studies have shown that wherever ART is available widely, it has reduced the mother-to-child transmission (MTCT) rates to 0--3.6%[@b19][@b20][@b21][@b22][@b23][@b24][@b25]. According to the most recent guidelines from US Department of Health and Human Services, LPV/r is the preferred PI for use in HIV-infected pregnant women[@b3]. Consequently, along with the growing number of HIV-infected women giving birth, concern has been raised on HIV-1 infection in newborns and the associated birth defects. Hence, considering these facts, the third objective of our study is to evaluate the effects of LPV/r in preventing MTCT of HIV, and also to evaluate its effect on the preterm and low body weight birth rates.

Results
=======

General study information
-------------------------

The search strategy initially identified 1,128 articles in total, of which 768 articles from Google Scholar and 360 articles from PubMed/Medline. Out of the total retrieved articles, the studies excluded after reviewing the titles and abstracts were 924 and 161, respectively. Of the remaining 43 studies that assessed LPV combined with other ART drugs to treat HIV-infected patients, 23 studies were finally excluded from the present study after detailed review for various reasons. Therefore, 8 articles[@b7][@b8][@b9][@b10][@b11][@b12][@b13][@b14] involving 2,584 ART-naïve patients, 4 articles[@b15][@b16][@b17][@b18] involving 1,124 ART-experienced patients, and 7 articles[@b19][@b20][@b21][@b22][@b23][@b24][@b25] involving 2,191 pregnant women were used in the meta-analyses. The detailed process of our literature search is shown in [Figure 1](#f1){ref-type="fig"}. The characteristics of these studies are listed in [Table 1](#t1){ref-type="table"}.

Efficacy and biological safety of LPV/r in ART-naïve and -experienced patients
------------------------------------------------------------------------------

Effectiveness of LPV/r was assessed in 13 studies on 15 cohorts of ART-naïve and -experienced patients. Efficacy was determined on the basis of the virologic response (viral load \< 50 copies/mL) rate after 48-weeks\' treatment and the changes in VL and CD4^+^ T lymphocyte count. Data related to changes in lipid levels were used to evaluate the safety. According to the information provided in the publications, meta-analyses were conducted on the virologic response of all the cohorts. The changes in CD4^+^ T lymphocyte count and the blood lipid levels were described without meta-analysis due to the lack of enough information. Additionally, although almost all 15 studies in [Table 1](#t1){ref-type="table"} have reported the baseline viral load data, only two[@b18][@b20] of them reported the viral load data after 48-weeks treatment. Therefore, viral load data were not included in our meta-analysis.

### Efficacy

For the efficacy measure of virologic response rate, data from 8 articles with 10 cohorts for ART-naïve patients and from 4 articles with 5 cohorts for ART-experienced patients were used in the meta-analysis. The virologic response rates in these studies and the combined virologic response rates are listed in [Table 2](#t2){ref-type="table"}. It was shown that the virologic response rate of ART-naïve patients with the use of LPV/r was statistically higher than that of ART-experienced patients, using either intention-to-treat (ITT) analysis (*p* = 0.018) or pre-protocol (PP) analysis (*p* = 0.019). Furthermore, ART drugs for ART-naïve patients were LPV/r combined with TDF in 5 cohorts and with non-TDF in the other 5 cohorts, respectively. The combined virologic response rate (72.3%, 95% CI: 67.5--77.1%) of LPV/r plus TDF arms was significantly greater than that of LPV/r plus non-TDF arms (65.5%, 95% CI: 61.2--69.8%, p = 0.047). The meta-analyses were illustrated in [Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}. On the other hand, PP analysis showed the combined virologic response rates of 89% and 81% for LPV/TDF and LPV/non-TDF arms, respectively.

The baseline CD4^+^ cell counts and the changes in CD4^+^ cell counts after 48-weeks\' treatment from baselines in each study are shown in [Table 3](#t3){ref-type="table"}.

### Safety

[Table 3](#t3){ref-type="table"} also depicts the assessed fasting blood lipid levels, including directly measured blood lipids values, at baseline and 48-weeks post-therapy. The combined incidence of grade 3 or 4 abnormal total cholesterol (defined as \>300 mg/dL) for ART-naïve patients was calculated as 13.1% (95% CI: 11.4--14.8%) using meta-analysis, which was statistically higher than that for ART-experienced patients (6.9%, 95% CI: 4.9--9.0%, p \< 0.001). Whereas, the combined incidence of grade 3 or 4 abnormal triglycerides (defined as \>750 mg/dL) for ART-naïve patients was 6.0% (95% CI: 4.8--7.1%), which was not statistically different from that for ART-experienced patients (5.5%, 95% CI: 3.7--7.3%, p = 0.363).

Efficacy of LPV/r in pregnant women
-----------------------------------

Seven studies assessed the anti-retroviral effects of LPV/r in 8 cohorts of pregnant women. The assessment included the MTCT rate of HIV and the rates of preterm birth (\<37 weeks gestation) and low birth weight (\<2500 g). In studies reporting MTCT, preterm delivery and low birth weight, rates ranged from 0.6 to 1.8%, 8.7 to 25% and 11.4 to 20.3%, respectively. Other information about these studies is shown in [Table 4](#t4){ref-type="table"}. The combined preterm delivery rate, low birth weight rate, and MTCT rate were 13.2% (95% CI: 10.9--15.5%), 16.2% (95% CI: 12.9--19.5%), and 1.1% (95% CI: 0.4--1.7%), respectively ([Figure 4](#f4){ref-type="fig"}).

Discussion
==========

At present, boosted PIs are the most recommended first-line therapy for NRTI- or non-nucleoside reverse-transcriptase inhibitors (NNRTI)-resistant patients and also the suggested therapy during the planning of pregnancy[@b3][@b4][@b5][@b6]. LPV/r is the first ritonavir-boosted PI and is most widely used as a standard comparator for other boosted PI regimens. Many RCT studies focused on the assessment of the effectiveness of LPV/r. Though RCTs can provide the highest levels of evidence, single studies still have insufficient statistical power. Therefore, we conducted a meta-analysis to evaluate and describe the efficacy, safety, and tolerability of LPV/r-based ART regimens in a large number of HIV-infected patients. Overall, HIV-infected people on an LPV/r-containing regimen experienced significant virologic and immunologic responses through their first year of therapy.

In the ITT analysis for ART-naïve patients, the proportion of individuals with respect to virologic response rate was slightly different between LPV/r plus TDF and LPV/r plus non-TDF arms (72.3% vs. 65.5%, p = 0.047). However, other studies (one RCT[@b11] and two non-RCTs[@b26][@b27]) comparing ABC/3TC- and TDF/FTC-based therapy with LPV/r in ART-naïve patients suggested no difference (68% vs. 67%, 63% vs. 67%, and 88% vs. 95%, respectively) in virologic response to HIV-1 RNA below 50 copies/mL after receiving therapy for 48 weeks. Our meta-analysis was based on a large number of patients from RCT studies, so the result will be more reliable. In this meta-analysis, the use of LPV/r in HIV-infected subjects with a first-line ART led to virological success in most patients. Even a previous study[@b9] showed that 98% of patients reached the virologic response level after receiving therapy for 48 weeks. On the other hand, the use of LPV/r in subjects failing a first-line ART also led to a virological success in more than half (55.7%) of the patients. Therefore, LPV/r played a major role in ushering in the era of boosted PI therapy, and in offering the first good option to patients who had failed prior therapy.

In addition, our results indicated that LPV/r can effectively improve the immunological outcome. After treatment for 48 weeks, CD4^+^ counts increased to 141--239 cells/mm^3^ from baseline. In the CASTLE study[@b12], a prospective, open-label, randomized study to determine the safety and efficacy of atazanavir/ritonavir compared to LPV/r, CD4^+^ counts increased to 219 cells/mm^3^ from baseline. Even for patients with severely impaired baseline immune function, in whom the initial median level of CD4^+^ count was only 54 cells/mm^3^, LPV/r showed significant immunological efficacy by boosting CD4^+^ counts to 239 cells/mm^3^ from baseline to week 48[@b14]. More importantly, ART-experienced patients showed remarkable immunological efficacy with elevated CD4^+^ counts of 121--169 cells/mm^3^ [@b15][@b16][@b17]. Hence, even in the ART-experienced patients, LPV/r still showed robust efficacy to elevate CD4^+^ counts with few virological failures.

Grade 3 or 4 treatment-related hyperlipemia was reported in ART patients. In 2 studies carried out by Ortiz *et al*.[@b8] and Molina *et al*.[@b12], the incidence of dyslipidemia in ART-naïve patients was 23% and 18%, respectively. Similarly, a greater risk of hypertriglyceridemia was found in ART-naïve patients in our analysis. We are encouraged that these data demonstrate that LPV/r was well tolerated in ART-experienced patients in terms of lipid levels, as the incidence of abnormal total cholesterol in ART-experienced patients was 6.9%, which was 13.1% in ART-naïve patients (p \< 0.001). Other drugs that could potentially influence triglyceride levels were well balanced between at baseline and during follow-up. However, in the meta-analysis, the number of individuals with available low-density lipoprotein measurements was lower than with the two other lipid factors, especially in the ART-experienced arm; nevertheless, in a clinical setting our results confirmed that LPV/r is a valid option which presents a good tolerability among the ART-experienced patients. Therefore, LPV/r is used as the second-line regimen with good tolerated in China. Consequently, it is highly recommended that lipid levels are measured before commencement of therapy and should be monitored periodically during follow-up.

Different studies have provided different answers to the question of whether the use of LPV/r-based ART during pregnancy confers an increased risk of preterm delivery. The meta-analysis of eight cohorts of 2,191 pregnant women with LPV/r resulted in a relatively low MTCT rate of 1.1%, preterm birth rate of 13.2%, and a low birth weight rate of 16.2%, which were similar to those of HIV-negative women in a small prospective cohort of six US centers[@b28]. However, it was lower than previously reported values which showed a prematurity rate of 19.1% in ART-treated HIV-infected women[@b29][@b30][@b31]. These meta-analysis findings showed that ART regimens currently being used to treat HIV-infected women during pregnancy are not associated with an increased risk of premature delivery and low birth weight. Therefore, it can be said that the LPV/r regimen is a relatively safe treatment option in terms of newborn health. The results from another systematic review[@b32] further suggested that there were no unique safety or efficacy concerns with the use of standard dose LPV/r as part of ART regimens in pregnant women.

A limitation of this study is that it only included publications in English. Moreover, for the meta-analysis of the efficacy of LPV/r for HIV-infected pregnant women, observational studies are prone to bias because the groups compared may be dissimilar in characteristics. Factors including local medical environments, maternal race, age, and previous obstetric history other than treatment might also be responsible for premature birth. It is also possible that different ART classes of agents, or even agents within each class, inconsistent research durations, and different time points of therapy might have different effects on the risk of premature delivery.

This study demonstrated sufficient evidence to show that LPV/r was an efficacious regimen for ART-naïve patients and was more tolerable for ART-experienced patients. In addition, LPV/r displayed a significant effect in preventing MTCT.

Methods
=======

Strategy for literature search
------------------------------

A computer-based literature search was conducted using search engines including Google Scholar and PubMed/Medline with 'lopinavir/ritonavir\' and 'HIV/AIDS\' as the search terms in the titles. Subsequently, literature on ART using LPV/r combined with other drugs was collected.

Study selection
---------------

Studies that assessed the effectiveness of LPV/r-based ART in HIV-infected patients, recruited adult HIV-infected patients, and gave the efficacy and/or safety outcomes were included in the current meta-analysis. Whereas the reviews of LPV/r treatment in HIV, pharmacokinetic studies of LPV/r in HIV-infected patients, studies that recruited HIV-infected children, duplicate publications or studies with similar data collection, and studies with incomplete data were excluded.

Study selection was performed by reviewing the titles and abstracts of all examined articles, followed by a detailed review of the eligible articles. This process was carried out independently by 2 researchers (Q. Y. Yang and T. Zhang) without prior consideration of the results. They came to a consensus through discussion after any disagreement.

Data extraction
---------------

Two researcher (J. Q. Chen and Y. L. Xu) independently extracted and then cross-checked the following data: the name of the first author, study design, publication year, the number of patients, analytic method, patients\' characteristics (whether received ART and ART drugs used), baseline information of each patient (viral load, CD4^+^ T cell count, total cholesterol, triglyceride and low-density lipoprotein), and relevant outcome data. For HIV-infected adults, the primary outcomes of efficacy and safety were the virologic response rate and fasting lipid levels (including directly measured blood lipids values), respectively. For pregnant women, the primary efficacy outcome was the mother-to-child transmission rate. Any disagreements were resolved by discussion and consensus.

Statistical analysis
--------------------

Statistical analyses were conducted by Stata, version 12 (StataCorp LP, USA). Heterogeneity for each combined rate was assessed by chi-square-based Q-test and the *I*^2^ statistic. Heterogeneity was considered as moderate to large when *P* \< 0.1 for Q-test or *I*^2^ \< 50%. Meta-analyses were conducted via random effects models for studies presenting moderate to large heterogeneity, otherwise, fixed effects models were used. Publication bias was evaluated by Begg\'s test. Two combined rates were compared by the method described in Altman\'s article[@b33].
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![Meta-analysis of virologic response rates for ART-naïve patients under (a) intention-to-treat analysis (heterogeneity: *I*^2^ = 78.9% and p \< 0.001; publication bias: p = 0.721); and (b) pre-protocal analysis (heterogeneity: *I*^2^ = 92.6% and p \< 0.001; publication bias: p = 0.221).](srep08528-f2){#f2}

![Meta-analysis of virologic response rates for treatment-experienced patients under (a) intention-to-treat analysis (heterogeneity: *I*^2^ = 88.4% and p \< 0.001; publication bias: p = 0.086); and (b) pre-protocol analysis (heterogeneity: *I*^2^ = 85.1% and p \< 0.001; publication bias: p = 0.089).](srep08528-f3){#f3}

![Meta-analysis of the efficacy for pregnant women in terms of (a) preterm birth rate (heterogeneity: *I*^2^ = 51.7% and p = 0.043, publication bias: p = 0.536), (b) low birth weight rate (heterogeneity: *I*^2^ = 67.4% and p = 0.005, publication bias: p = 1.000) and (c) mother-to-child transmission rate of HIV (heterogeneity: *I*^2^ = 0% and p = 0.828, publication bias: p = 0.707).](srep08528-f4){#f4}

###### General information of studies included in the meta-analysis

  Authors                           Publication year   Number of patients    Drug combination[†](#t1-fn3){ref-type="fn"}     Analytic method   Study design
  -------------------------------- ------------------ -------------------- ------------------------------------------------ ----------------- ---------------
  ART-naïve patients                                                                                                                                  
  Walmsley S *et al*.[@b7]                2002                326                     d4T-3TC + LPV/r/Nelfinavir                 ITT/PP             RCT
  Ortiz R *et al*.[@b8]                   2008                346                    TDF-FTC + LPV/r/darunavir/r                   ITT              RCT
  Delfraissy JF *et al*.[@b9]             2008                 53                          AZT-3TC + LPV/r                       ITT/PP             RCT
  Johnson MA *et al*.[@b10]               2006                115                          TDF-FTC + LPV/r                       ITT/PP             RCT
  Johnson MA *et al*.[@b10]               2006                 75                          TDF-FTC + LPV/r                       ITT/PP             RCT
  Smith KY *et al*.[@b11]                 2009                345                          TDF-FTC + LPV/r                         ITT              RCT
  Smith KY *et al*.[@b11]                 2009                343                          ABC-3TC + LPV/r                         ITT              RCT
  Molina JM *et al*.[@b12]                2008                443                    TDF-FTC + LPV/r/atazanavir/r                  ITT              RCT
  Eron J Jr *et al*.[@b13]                2006                444                  ABC-3TC + LPV/r/fosamprenavir-r                 ITT              RCT
  Sierra-Madero J *et al*.[@b14]          2010                 94                        AZT-3TC + LPV/r/EFV                     ITT/PP             RCT
  ART-experienced patients                                                                                                                            
  Cohen C *et al*.[@b15]                  2005                150              AZT-3TC/d4T-3TC/AZT-DDI/d4T-DDI + LPV/r           ITT/PP             RCT
  Zajdenverg R *et al*.[@b16]             2010                300           ≥2 NRTIs (AZT/3TC/ABC/DDI/d4T/TDF/FTC) + LPV/r       ITT/PP             RCT
  Zajdenverg R *et al*.[@b16]             2010                299           ≥2 NRTIs (AZT/3TC/ABC/DDI/d4T/TDF/FTC) + LPV/r       ITT/PP             RCT
  Johnson M *et al*.[@b17]                2005                123             TDF + one NRTI(DDI/d4T/3TC/AZT/ABC)+ LPV/r         ITT/PP             RCT
  De Meyer S *et al*.[@b18]               2007                252                     (NRTI + one NNRTI) + LPV/r                   ITT              RCT
  Pregnant women                                                                                                                                      
  Roberts SS *et al*.[@b19]               2009                890                               LPV/r                              ITT          Prospective
  Senise J *et al*.[@b20]                 2008                 64                          AZT-3TC + LPV/r                         ITT         Retrospective
  de Vincenzi I[@b21]                     2011                401                          AZT-3TC + LPV/r                         ITT              RCT
  Azria E *et al*.[@b22]                  2009                100              AZT-3TC/AZT-other NRTI/AZT-alone+ LPV/r             ITT         Retrospective
  Peixoto MF *et al*.[@b23]               2011                164                               LPV/r                              ITT          Prospective
  Peixoto MF *et al*.[@b23]               2011                 70                               LPV/r                              ITT          Prospective
  Villatoro CM *et al*.[@b24]             2012                219                   LPV/r alone or AZT-3TC + LPV/r                 ITT         Retrospective
  Shapiro RL *et al*.[@b25]               2010                283                      AZT-3TC/ABC-3TC + LPV/r                     ITT          Prospective

ITT: intention-to-treat; PP: per-protocol; RCT: randomized controlled trial.

There were two different dose groups of ART-experienced patients with LPV/r tablets 800/200 mg QD (n = 300) or 400/100 mg BID (n = 299) in one study conducted by Zajdenverg R et al.

^†^LPV/r in combination with an optimized background regimen of at least 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). The most commonly used drugs are TDF/AZT/D4T/ABC,DDI,3TC/FTC.

###### Virologic response rates for ART-naïve and -experienced patients using intention-to-treat analysis and pre-protocol analysis

                                Using ITT analysis                   Using PP analysis                          
  -------------------------- ---------------------- ------------------------------------------------- --------- ------------------------------------------------
  ART-naïve patients                53--78%          68.8% (64.8--72.9%) [†](#t2-fn2){ref-type="fn"}   62--98%   83.8% (73.6--94.0%)[‡](#t2-fn3){ref-type="fn"}
  ART-experienced patients          46--71%                        55.7% (47.1--64.2%)                 54--76%                66.4% (57.3--75.6%)

ITT: intention-to-treat; PP: per-protocol; CI: confidence interval.

^†^Compared to ART-experienced patients, p = 0.018;

^‡^Compared to ART-experienced patients, p = 0.019.

###### Changes in CD4^+^ count and blood lipid levels (48-weeks post-treatment)

                                    Total cholesterol (mg/dL)       Triglycerides (mg/dL)       Low-density lipoprotein (mg/dL)   CD4^+^ count(cells/mm^3^)                                                                                                                                 
  -------------------------------- --------------------------- ------------------------------- --------------------------------- --------------------------- -------------------------------- ----- ----- ------------------------------- ---- -------------------------------------------- -------------------------------------------
  ART-naïve patients                                                                                                                                                                                                                                                                                              
  Walmsley S *et al*.[@b7]                     NA               53[†](#t3-fn1){ref-type="fn"}                  9                             NA               125[†](#t3-fn1){ref-type="fn"}   9.3   NA                 NA                                         260                                          207
  Ortiz R *et al*.[@b8]                        NA                            NA                               23                             NA                             NA                 11    NA                 NA                 10                      218                                          141
  Johnson MA *et al*.[@b10]                    159              27[†](#t3-fn1){ref-type="fn"}                 NA                             137              82[†](#t3-fn1){ref-type="fn"}     5    96    14[†](#t3-fn1){ref-type="fn"}   NA   214 (116--380) [‡](#t3-fn5){ref-type="fn"}                      185
  Johnson MA *et al*.[@b10]                    168              27[†](#t3-fn1){ref-type="fn"}                 NA                             136              76[†](#t3-fn1){ref-type="fn"}     4    102   13[†](#t3-fn1){ref-type="fn"}   NA    232 (95--339)[‡](#t3-fn5){ref-type="fn"}                       188
  Molina JM *et al*.[@b12]                     147                           185                              18                             110                           168                  4    91                 108                NA                      204                                          219
  Eron J Jr *et al*.[@b13]                     157                           210                               9                             117                           195                  8    97                 120                NA    194 (79--287)[‡](#t3-fn5){ref-type="fn"}    191 (124--287)[‡](#t3-fn5){ref-type="fn"}
  Sierra-Madero J *et al*.[@b14]               NA               63[†](#t3-fn1){ref-type="fn"}                 NA                             NA               116[†](#t3-fn1){ref-type="fn"}   NA    NA    10[†](#t3-fn1){ref-type="fn"}   NA   52 (37.1--66.8)[‡](#t3-fn5){ref-type="fn"}                      239
  ART-experienced patients                                                                                                                                                                                                                                                                                        
  Cohen C *et al*.[@b15]                       167                           190                              NA                             162                           211                 NA    97                 103                NA                      256                                          169
  Zajdenverg R *et al*.[@b16]                  NA                            NA                               6.5                            NA                             NA                 4.8   NA                 NA                 NA                     239.3                                         153
  Zajdenverg R *et al*.[@b16]                  NA                            NA                               7.5                            NA                             NA                 6.4   NA                 NA                 NA                     268.3                                         122

^†^Elevated value;

^\#^Grade 3 or 4 abnormal: defined as \>300 mg/dL except for Molina\'s study (Ref. [@b12]);

^\$^Grade 3 or 4 abnormal: defined as \>750 mg/dL;

^∧^Grade 3 or 4 abnormal was not mentioned;

^‡^median (quartiles).

###### General information about LPV/r treatment of pregnant women

                                          Age at delivery  (year)               Baseline CD4^+^ count  (cells/mm^3^)          Baseline viral load (log10 copies/mL)       Vaginal delivery (%)   MTCT (%)   PD (%)   LBW (%)
  ----------------------------- ------------------------------------------- -------------------------------------------- ----------------------------------------------- ---------------------- ---------- -------- ---------
  Roberts SS *et al.*[@b19]                       13--48                                         NA                                            NA                                  NA               NA       13.4     19.2
  Senise J *et al*.[@b20]        29.4 (16--41)[\#](#t4-fn1){ref-type="fn"}   289 (13--811)[\*](#t4-fn2){ref-type="fn"}    4.28 (0-- ≥ 5.88)[\*](#t4-fn2){ref-type="fn"}            11              0.8       25.0     20.3
  de Vincenzi I[@b21]             27 (24--31)[\*](#t4-fn2){ref-type="fn"}    336 (282--408)[∧](#t4-fn3){ref-type="fn"}    4.23 (3.66--4.75)[∧](#t4-fn3){ref-type="fn"}             89              1.8       13.2     11.4
  Azria E *et al*.[@b22]          32.4 ± 5.0[\$](#t4-fn4){ref-type="fn"}      361 (8--858)[\*](#t4-fn2){ref-type="fn"}    3.6 (\<1.7--5.4)[\*](#t4-fn2){ref-type="fn"}             45              1.0       21.0     17.0
  Peixoto MF *et al*.[@b23]       29.6 ± 5.5[\$](#t4-fn4){ref-type="fn"}     486.1 ± 292.7 [\$](#t4-fn4){ref-type="fn"}       2.6 ± 1.0[\$](#t4-fn4){ref-type="fn"}                NA              0.6       9.8      20.2
  Peixoto MF *et al*.[@b23]       27.1 ± 6.4[\$](#t4-fn4){ref-type="fn"}     535.4 ± 303.9 [\$](#t4-fn4){ref-type="fn"}       3.0 ± 0.7[\$](#t4-fn4){ref-type="fn"}                NA              0.7       8.7      15.9
  Villatoro CM *et al*.[@b24]     26 (16--43)[\*](#t4-fn2){ref-type="fn"}    329 (2--1034)[\#](#t4-fn1){ref-type="fn"}     4.82 (0--6.26)[\#](#t4-fn1){ref-type="fn"}              4               1.4       10.6      NA
  Shapiro RL *et al*.[@b25]                         25                       403 (297--514)[∧](#t4-fn3){ref-type="fn"}    3.96 (3.34--4.60)[∧](#t4-fn3){ref-type="fn"}             NA               NA       14.8     13.1

^\#^Mean (range);

\*median (range);

^∧^median (quartiles);

^\$^mean ± standard deviation.

MTCT: mother-to-child transmission; PD: preterm delivery (\<37 weeks gestation); LBW: low birth weight (\<2,500 g).

[^1]: These authors contributed equally to this work.
